Acorda Therapeutics, Inc.
NASDAQ: ACOR0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Global Select
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- CEO
- Ron Cohen
- Employees
- 102
- Headquarters
- Ardsley, United States
- IPO year
- 2006
- Market cap
- $821.0K
- Website
- https://www.acorda.com
Loading ACOR…
Loading profile data…Frequently asked questions about ACOR
What does Acorda Therapeutics, Inc. (ACOR) do?
Acorda Therapeutics, Inc. is a biopharmaceutical firm dedicated to discovering, developing, and commercializing treatments for conditions affecting the nervous system, primarily within the United States. Its current product offerings include Ampyra (dalfampridine), an oral medication prescribed to enhance walking ability in individuals with mult...
Where does ACOR trade?
Acorda Therapeutics, Inc. (ACOR) trades on the NASDAQ Global Select.
What sector is ACOR in?
Acorda Therapeutics, Inc. (ACOR) operates in the Healthcare sector, specifically in the Drug Manufacturers - Specialty & Generic industry.
Who is the CEO of Acorda Therapeutics, Inc.?
Ron Cohen is the chief executive officer of Acorda Therapeutics, Inc. (ACOR).
Where is Acorda Therapeutics, Inc. headquartered?
Acorda Therapeutics, Inc. is headquartered in United States.
Does ACOR pay a dividend?
Acorda Therapeutics, Inc. (ACOR) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did ACOR go public?
Acorda Therapeutics, Inc. (ACOR) completed its initial public offering in 2006.